ImmunityBio (NasdaqGS:IBRX) Q4 2025 Earnings call March 03, 2026 04:30 PM ET Company ParticipantsClara Dong - VP, Equity Research in BiotechnologyJason Kolbert - Managing Director, Head of Equity ResearchPatrick Soon-Shiong - Founder, Executive Chairman, and Global Chief Scientific and Medical OfficerRichard Adcock - President and CEOConference Call ParticipantsAndres Maldonado - Senior Biotechnology AnalystEdward Tenthoff - Biotech Equity Research AnalystJeet Mukherjee - VP and Biotechnology AnalystOperato ...

Cumberland Pharmaceuticals (NasdaqGS:CPIX) Q4 2025 Earnings call March 03, 2026 04:30 PM ET Company ParticipantsA.J. Kazimi - CEOEmily Kent - Public Relations Account ManagerJohn Hamm - CFOTodd Anthony - VP of Organizational DevelopmentOperatorGood afternoon, welcome to Cumberland Pharmaceuticals 2025 financial report and company update. This call is being recorded at the company's request and will be archived on its website for one year from today's date. I'd like to turn it over to Emily Kent from Dalton ...

Financial Data and Key Metrics Changes - The company reported record full-year revenue of $104.1 million, a 2% increase over 2024's $102 million [25] - Fourth quarter revenues were $24.8 million, representing a 6% increase year-over-year [22] - Adjusted EBITDA for the full year was $12.6 million, down from $14.4 million in the prior year [25] - GAAP net loss for the year was approximately $9.4 million, compared to a loss of $9.2 million in the previous year [27] Business Line Data and Key Metrics Changes - The ShotSpotter solution generated $67.6 million in ARR, with expectations to add approximately $8.3 million in 2026 [9] - SafePointe bookings reached $1.6 million from 11 customers, with an anticipated contribution of $4 million in ARR for 2026 [5][14] - CrimeTracer exited 2025 with $8.1 million in ARR, with an expected addition of $3.1 million in 2026 [11] - PlateRanger is expected to contribute $1.5 million in new ARR in 2026 [12] Market Data and Key Metrics Changes - The company exited 2025 with an ARR of $95.4 million, with a projected growth of approximately 15% or $14.6 million in 2026 [5] - Revenue retention rate for 2025 was 99%, impacted by the non-renewal of the Chicago ShotSpotter contract [28] Company Strategy and Development Direction - The company is focused on expanding its public safety solutions through innovative technology and AI integration [7][8] - Strategic investments are being made in growth areas like SafePointe and operational efficiencies [20] - The company aims to enhance customer engagement by introducing more solutions within its platform [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth of the public safety solutions market despite headwinds faced in 2025 [4] - The company is adjusting its full-year revenue guidance to $109 million-$111 million due to delays in expected bookings [29] - Management remains optimistic about long-term value from potential contracts despite temporary setbacks [32] Other Important Information - The company has strengthened its sales team by adding new leaders with experience in scaling operations [15][16] - The board is reviewing business operations to identify efficiency opportunities [42][43] Q&A Session Summary Question: What verticals are most prominent for SafePointe? - The healthcare vertical has shown significant success due to the passive nature of the weapons detection system [36] Question: Status of CaseBuilder deployment in NYPD Corrections? - Progress is being made with new applications for the New York City Department of Correction [38] Question: Expected attrition for ShotSpotter this year? - Total ARR attrition is expected to be about $3 million, with a significant portion related to ShotSpotter [39] Question: Details on the board review for cost-saving measures? - The board is engaged in evaluating opportunities for greater efficiencies within the organization [42][43] Question: Insights on sniper gunshot detection technology? - The company is developing a perimeter-based sniper detection solution, focusing initially on utility substations [46][48] Question: Clarification on SafePointe bookings and ARR expectations? - The company expects to achieve $4 million in ARR from SafePointe in 2026, with a strong pipeline in the healthcare sector [51] Question: Trends in international revenue growth? - The company anticipates new deployments in three countries, with positive expansion expected in Brazil, Uruguay, and South Africa [64]

Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $26.6 million, representing a 24% year-over-year growth compared to $21.5 million in the prior year quarter [4][18] - RNS System revenue was $22.4 million, up 26% year-over-year, contributing significantly to overall revenue growth [4][18] - Gross margin improved to 77.4%, up from 75.4% in the fourth quarter of 2024, driven by higher margin RNS revenue and manufacturing efficiencies [19] - Adjusted EBITDA was positive at $900,000 for the fourth quarter, marking a $1.9 million improvement year-over-year [22] Business Line Data and Key Metrics Changes - The core RNS business showed strong performance with a growth rate of 29% in the second half of 2025 [5] - Service revenue from data collaborations totaled approximately $890,000 in the fourth quarter [18] - Revenue from DIXI Medical was approximately $3 million, a decline of 4% compared to the fourth quarter of 2024, as the company worked to sell existing inventory before the end of the commercial partnership [18] Market Data and Key Metrics Changes - The majority of growth came from Level 4 centers, indicating increased adoption and utilization of the RNS System [6] - The company reached new highs in prescribers, accounts, and patient pipeline, reflecting broad-based momentum across the business [5] Company Strategy and Development Direction - The company is focused on deepening adoption within the adult focal epilepsy indication while preparing for future indication expansion [5] - Investments are being made in the commercial organization, including sales representative additions and nurse navigator resources to enhance patient navigation through the treatment process [9] - The company aims to expand its RNS therapy access through community pathways and improve referral management [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a long-term growth trajectory of at least 20% in the core RNS business [7] - The company reiterated its full-year 2026 revenue guidance of $98 million to $100 million, assuming core RNS growth of 20%-22% [8][26] - Management highlighted the potential for a transformational year in 2026, driven by ongoing market momentum and new product developments [17][34] Other Important Information - The company submitted a PMA supplement to the FDA for an expanded indication in idiopathic generalized epilepsy (IGE), supported by significant clinical data [10] - The SeizureID tool, designed to enhance physician workflow and improve patient outcomes, is expected to receive approval in the first half of 2026 [12] Q&A Session Summary Question: How quickly can the company translate from IGE approval to revenue collection? - Management indicated that extending coverage in the private payer community is essential and that preparations are already underway to target key payers [38] Question: What is the impact of pricing on RNS growth in the fourth quarter? - Management noted that mid-single digit pricing increases have been consistent, contributing positively to gross margins without any significant changes in Q4 [50] Question: What is the current state of capacity dynamics across implanting centers? - Management stated that there is sufficient capacity in the channel for prescribers and that nurse navigators are being employed to facilitate patient flow through the referral process [60][61] Question: What is the logistics behind the SeizureID opportunity? - SeizureID will be part of the RNS System offering, aimed at improving efficiency for clinicians without additional costs for access [66]

Crexendo (NasdaqCM:CXDO) Q4 2025 Earnings call March 03, 2026 04:30 PM ET Company ParticipantsDoug Gaylor - President and COOEric Martinuzzi - Founding Partner an COOGeorge Sutton - Partner and Co-Director of ResearchJeff Korn - CEO and Chairman of the BoardJon D. Brinton - Chief Revenue OfficerMatt Maus - Equity Research AssociateRon Vincent - CFOConference Call ParticipantsJoshua Reilly - Managing Director and Senior Research AnalystMike Latimore - Managing Director and Equity AnalystOperatorPlease note, ...

Crexendo (NasdaqCM:CXDO) Q4 2025 Earnings call March 03, 2026 04:30 PM ET Company ParticipantsDoug Gaylor - President and COOEric Martinuzzi - Founding Partner an COOGeorge Sutton - Partner and Co-Director of ResearchJeff Korn - CEO and Chairman of the BoardJon D. Brinton - Chief Revenue OfficerMatt Maus - Equity Research AssociateRon Vincent - CFOConference Call ParticipantsJoshua Reilly - Managing Director and Senior Research AnalystMike Latimore - Managing Director and Equity AnalystOperatorPlease note, ...

Rigel Pharmaceuticals (NasdaqGS:RIGL) Q4 2025 Earnings call March 03, 2026 04:30 PM ET Company ParticipantsAshley Aloupis - Equity Research AssociateDavid Santos - Chief Commercial OfficerDean Schorno - CFOJoe Pantginis - Managing Director of Equity ResearchLisa Rojkjaer - EVP and Chief Medical OfficerRaul Rodriguez - President and CEORaymond Furey - EVP, General Counsel and Corporate SecretaryConference Call ParticipantsFarzin Haque - SVP and Biotechnology Equity Research AnalystKristen Kluska - Director a ...

Financial Performance - The company reported combined revenues of $13.7 million for Q4 2025, a 31% increase year-over-year, and total revenues of $44.5 million for the full year, up 18% from 2024 [6][22] - Adjusted earnings improved by over $2 million to $1.7 million or $0.11 per share, with cash flow from operations increasing by $5.5 million to just under $5 million for the year [6][25] - The net loss for Q4 was approximately $1.4 million, and for the full year, it was $2.9 million, both significantly improved compared to 2024 [24] Business Line Performance - Revenues by product for Q4 included $3.1 million for Kristalose, $3.3 million for Sancuso, $2.8 million for Vibativ, $0.9 million for Caldolor, and $3.3 million for Talicia [22] - For the full year, product revenues totaled $10.5 million for Kristalose, $11.9 million for Sancuso, $9.4 million for Vibativ, $4.7 million for Caldolor, and $3.3 million for Talicia [23] Market Expansion - Vibativ received regulatory approval in China and was launched in Saudi Arabia, creating significant new opportunities [7] - The company also received regulatory approval for its ibuprofen injection product in Mexico, further expanding its international market presence [7] Strategic Developments - The company acquired Talicia, an FDA-approved treatment for Helicobacter pylori infections, enhancing its gastrointestinal care portfolio [8] - A J-code for Caldolor was issued by CMS, improving product access and supporting its growth as a standard of care for pain and fever [8] Management Commentary - Management expressed optimism about the company's future, highlighting strong financial performance, global expansion, and advancements in the clinical pipeline [5][29] - The company is targeting double-digit revenue growth for 2026, driven by in-line brands and the new addition of Talicia [30] Other Important Information - The company strengthened its balance sheet by increasing shareholder equity and reducing its line of credit balance by over $10 million [6][7] - Cumberland holds over $54 million in tax net operating loss carryforwards, primarily from prior stock option exercises [28] Q&A Session Summary - There were no questions from participants during the call, and management expressed willingness to engage in private discussions with shareholders if desired [32][33]

Rigel Pharmaceuticals (NasdaqGS:RIGL) Q4 2025 Earnings call March 03, 2026 04:30 PM ET Company ParticipantsAshleigh Acker - Biotechnology Equity Research AssociateDave Santos - Chief Commercial OfficerDean Schorno - CFOJoe Pantginis - Managing Director of Equity ResearchLisa Rojkjaer - EVP and Chief Medical OfficerRaul Rodriguez - President and CEORay Furey - EVP, General Counsel and Corporate SecretaryConference Call ParticipantsFarzin Haque - SVP and Biotechnology Equity Research AnalystKristen Kluska - D ...

SoundThinking (NasdaqCM:SSTI) Q4 2025 Earnings call March 03, 2026 04:30 PM ET Company ParticipantsAlan Stewart - CFOAlex Latimore - Research AssociateElle Niebuhr - Equity Research AssociateRalph Clark - CEOConference Call ParticipantsJeremy Hamblin - Senior Research AnalystTrevor Walsh - Director and Senior Equity Research AnalystOperatorGood afternoon, and welcome to SoundThinking's fourth quarter and full year 2025 earnings conference call. My name is Diego, and I will be your operator for today's call. ...